Feature

‘Right to try’ bill passes House


 

Terminal patients who have exhausted all approved drug options would be able to seek out investigational treatments – even if they do not qualify for clinical trials – under a bill passed in the U.S. House, despite opposition from more than 100 patient and physician groups.

The Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right To Try Act of 2018 (H.R. 5247) passed by a 267-149 vote, promising improved access to experimental treatments.

Alicia Ault/Frontline Medical News
H.R. 5247 creates a new, alternative pathway for patients who do not qualify for clinical trials to access experimental medications and requires informed consent to access these treatments.

For an unapproved drug to be made available to patients, it must have an active application that is not subject to any kind of clinical hold. Sponsors and manufacturers must notify the Food and Drug Administration when an unapproved drug is made available to the patient.

Pages

Next Article:

Women in medicine shout #MeToo about sexual harassment at work
   Comments ()

Related Articles